DFTX is trading at $38.49 (+6.38%) in pre-market following a sharp rerating driven by positive Phase 3 Emerge data for DT120 ODT in major depressive disorder.
- Momentum is being sustained by follow-on analyst upgrades and continued investor focus on the recent clinical catalyst.
- Market attention is also shifting toward the company’s upcoming Q2/Q3 2026 readouts, which are expected to provide further catalysts for the stock.